Volume 118, Issue 6 , Pages 1375-1381, December 2006
Sex-related differences in immune development and the expression of atopy in early childhood
Background
Sex and age are known to influence the clinical expression of asthma and allergic diseases.
Objective
We sought to evaluate whether immune response profiles also vary by sex and age.
Methods
We performed a prospective birth cohort study (Childhood Origins of Asthma) designed to evaluate interactions among age, sex, immune responses, and virus infections on the development of asthma and allergic diseases. Two hundred eighty-nine subjects were enrolled at birth, and 275 maintained prospective follow-up for 3 years. Cytokine response profiles at birth, 1, and 3 years of age; rates of wheezing, atopic dermatitis, and viral illnesses; and biomarkers of atopy, including total and specific IgE levels and peripheral eosinophil counts, were evaluated.
Results
PHA-induced IFN-γ responses were higher in boys at 1 year of age (median, 35 vs 19 pg/mL; P < .001) and at 3 years of age (median, 282 vs 181 pg/mL; P = .07). Among children who wheezed during the third year of life, boys had increased IFN-γ, IL-5, and IL-13 responses at age 3 years (P < .001, P = .008, and P = .01, respectively). Boys also demonstrated increased rates of sensitization (P = .05 at year 1), total IgE levels (P = .03 at year 1 and P = .006 at year 3), and peripheral eosinophil counts (2.62 vs 1.85; P = .05 at year 3).
Conclusion
Sex-specific differences in immune responses develop during early childhood; some of these differences developmentally proceed, whereas others occur in parallel to the clinical expression of various atopic phenotypes.
Clinical implications
The differential expression of atopic diseases between boys and girls in early childhood is accompanied by sex-specific differences in immune response profiles.
Key words: Cytokine, IFN-γ, IL-5, IL-13, IL-10, sex, wheezing, atopy, allergic sensitization, birth cohort
Abbreviations used: COAST, Childhood Origins of Asthma, RSV, Respiratory syncytial virus
Supported by National Institutes of Health grants 1R01HL61879-01 and 1P01HL70831-01.Disclosure of potential conflict of interest: R. F. Lemanske, Jr, has consultant arrangements with GlaxoSmithKline and AstraZeneca and is on the speakers' bureau for AstraZeneca, Aventis, Merck, and GlaxoSmithKline. The rest of the authors have declared that they have no conflict of interest.
PII: S0091-6749(06)01909-9
doi:10.1016/j.jaci.2006.09.008
© 2006 American Academy of Allergy, Asthma and Immunology. Published by Elsevier Inc. All rights reserved.
Volume 118, Issue 6 , Pages 1375-1381, December 2006
